At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Closed 02-10 16:09:14
17.140
+0.840
+5.15%
High17.400Low16.300Vol5.09M
Open16.300D1 Closing16.300Amplitude6.75%
Mkt Cap17.00BTradable Cap17.00BTotal Shares992.00M
T/O86.94MT/O Rate0.51%Tradable Shares992.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma (01672) Announces 69.256 Million New Shares Issued and Provides Share Repurchase Update
Bulletin Express  ·  18:24
Ascletis Pharma (01672) Announces 69.256 Million New Shares Issued and Provides Share Repurchase Update
Ascletis Pharma (1672) Announces Completion of New Share Placement Under General Mandate
Bulletin Express  ·  17:45
Ascletis Pharma (1672) Announces Completion of New Share Placement Under General Mandate
ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds
Stock News  ·  17:44
ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds
Ascletis Pharma platziert 69,26 Millionen neue Aktien bei Investoren
Reuters  ·  17:30
Ascletis Pharma platziert 69,26 Millionen neue Aktien bei Investoren
ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential
Stock News  ·  14:54
ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
Tiger Newspress  ·  10:11
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Tiger Newspress  ·  02-09 10:12
HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term Capital in China's Core Innovative Drug Assets
ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase
Stock News  ·  02-09 09:46
ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase
Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications
Stock News  ·  02-05
Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications
Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?
Simply Wall St.  ·  02-04
Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Dow Jones  ·  02-04
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026
Bulletin Express  ·  02-03
Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026
Ascletis Pharma Seeks HK$843 Million via Share Offering
MT Newswires Live  ·  02-03
Ascletis Pharma Seeks HK$843 Million via Share Offering
BRIEF-Ascletis Pharma To Place 69.3 Million Shares
Reuters  ·  02-03
BRIEF-Ascletis Pharma To Place 69.3 Million Shares
ASCLETIS-B (01672) Proposes Placement of 69.256 Million Shares at Approximately 4% Discount, Targeting Net Proceeds of About HK$835.3 Million
Stock News  ·  02-03
ASCLETIS-B (01672) Proposes Placement of 69.256 Million Shares at Approximately 4% Discount, Targeting Net Proceeds of About HK$835.3 Million
Ascletis Pharma kündigt Privatplatzierung neuer Aktien an
Reuters  ·  02-03
Ascletis Pharma kündigt Privatplatzierung neuer Aktien an
Ascletis Pharma Inc - to Place 69.3 Mln Shares at HK$12.18 per Share
THOMSON REUTERS  ·  02-03
Ascletis Pharma Inc - to Place 69.3 Mln Shares at HK$12.18 per Share
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Reuters  ·  02-02
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance
Simply Wall St.  ·  02-02
Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance
BRIEF-Ascletis Pharma Gets Positive Topline Results From Phase III Open-Label Study Of Denifanstat
Reuters  ·  01-29
BRIEF-Ascletis Pharma Gets Positive Topline Results From Phase III Open-Label Study Of Denifanstat

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--